1878. Expanding Kentucky’s “One and Done” Tradition: Lipoglycopeptide Administration in the Emergency Department at a Tertiary, Academic Medical Center

Abstract

Background

Acute bacterial skin and skin structure infection (ABSSSI) incidence continues to rise, accounting for around 3.5 million emergency department (ED) visits per year in the United States. Dalbavancin and oritavancin are lipoglycopeptides with long half-lives allowing for single dose treatment options for eligible patients presenting with ABSSSIs in the ED, avoiding an inpatient admission. The objective of this study was to investigate the financial outcomes of utilizing these agents in the ED.

Methods

This was a single-center, retrospective study in adult patients with ABSSSIs that received a lipoglycopeptide in the ED at an academic medical center from April 2016 to February 2018. A multidisciplinary institutional guideline was developed and implemented in April 2016. Data were documented in the electronic medical record and/or REDCap™ database. A comparator group was identified by utilizing similar ICD-10 codes for patients that were admitted for ABSSSI. Variable direct cost-avoidance was examined to explore the financial implication of lipoglycopeptide treatment in this population.

Results

The average length of stay in the comparator group who were admitted for ABSSSIs during the predefined time period was 4.3 days. Because patients receiving a lipoglycopeptide did not require admission for intravenous antibiotics, 94.6 patient-days were avoided increasing the capacity by 14.1 patients. Overall, 22 patients received either dalbavancin ( n = 18) or oritavancin ( n = 4). The age was 40.8 ± 13.2 years for the study group with 55% male. The age of the comparator group was 40.5 ± 19.7 years. All patients were discharged home from the ED without being admitted. Two patients were readmitted for treatment failure requiring IV antibiotics. Despite 2 of 22 patients receiving a lipoglycopeptide without insurance, the variable direct cost avoidance was $4,560 per case, or $1,060 per day.

Conclusion

The use of lipoglycopeptides offers patient convenience and financial benefits, warranting its consideration for use in the ED at tertiary academic medical centers.

Disclosures

All authors: No reported disclosures.